TLX vs AB Comparison

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (41%), and private (18%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of February 2026, the company had $880.0 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (40%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.